Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., Lancent Rheumatology, 10.1016/S2665-9913(20)30227-7 (Peer Reviewed)
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Rheumatic disease patients on HC Q had a lower risk of COVID-19 than those on other disease-modifying anti-rheumatic drugs, OR 0.09 (0.01–0.94), p=0.044 after adjusting for age, sex, smoking, systemic lupus erythematosus, infection in other family members, and comorbidities. 43 patients with rheumatic disease and COVID-19 exposure.
Please send us corrections, updates, or comments: